X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (18) 18
humans (15) 15
adult (13) 13
female (12) 12
male (11) 11
abridged index medicus (9) 9
adolescent (8) 8
article (8) 8
double-blind method (7) 7
child (6) 6
diabetes mellitus, type 1 - drug therapy (6) 6
systemic sclerosis (6) 6
alefacept (5) 5
endocrinology & metabolism (5) 5
middle aged (5) 5
rheumatology (5) 5
treatment outcome (5) 5
type 1 diabetes (5) 5
young adult (5) 5
analysis (4) 4
diabetes (4) 4
double-blind (4) 4
scleroderma (4) 4
therapy (4) 4
c-peptide - metabolism (3) 3
care and treatment (3) 3
clinical trials (3) 3
cyclophosphamide (3) 3
cyclophosphamide - adverse effects (3) 3
cyclophosphamide - therapeutic use (3) 3
diabetes mellitus, type 1 - blood (3) 3
diabetes mellitus, type 1 - immunology (3) 3
drug therapy (3) 3
hypoglycemia (3) 3
immunology (3) 3
medicine, general & internal (3) 3
peptides (3) 3
randomized controlled trials as topic (3) 3
research (3) 3
risk factors (3) 3
time factors (3) 3
transplantation (3) 3
aged (2) 2
antilymphocyte serum - therapeutic use (2) 2
antirheumatic agents - therapeutic use (2) 2
association (2) 2
beta-cell function (2) 2
c-peptide (2) 2
children (2) 2
classification (2) 2
complications and side effects (2) 2
dosage and administration (2) 2
dose d-penicillamine (2) 2
dose-response relationship, drug (2) 2
funding (2) 2
genetic aspects (2) 2
glycemic control (2) 2
hematopoietic stem cell transplantation - adverse effects (2) 2
hypoglycemic agents - therapeutic use (2) 2
immune intervention (2) 2
immunologic memory - drug effects (2) 2
independence (2) 2
infant (2) 2
infectious diseases (2) 2
insulin (2) 2
internal medicine (2) 2
interstitial lung disease (2) 2
islet function (2) 2
lupus (2) 2
lymphocytes (2) 2
medical education (2) 2
mellitus (2) 2
metabolism (2) 2
monoclonal antibodies (2) 2
mortality (2) 2
new-onset t1d (2) 2
nod mice (2) 2
north carolina (2) 2
other (2) 2
patients (2) 2
phase-2 trial (2) 2
preservation (2) 2
preventive health services - standards (2) 2
primary health care - standards (2) 2
pulse cyclophosphamide (2) 2
recombinant fusion proteins - administration & dosage (2) 2
scleroderma, systemic - drug therapy (2) 2
scleroderma, systemic - mortality (2) 2
scleroderma, systemic - therapy (2) 2
sclerosis (2) 2
skin (2) 2
stem cells (2) 2
stem-cell transplantation (2) 2
studies (2) 2
survival (2) 2
teplizumab (2) 2
toxicity (2) 2
transplantation, autologous (2) 2
transplants & implants (2) 2
treatment (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 08/2015, Volume 125, Issue 8, pp. 3285 - 3296
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2018, Volume 378, Issue 1, pp. 35 - 47
Scleroderma is a life-threatening autoimmune disease in need of more effective treatment. A randomized trial of myeloablative therapy followed by autologous... 
MEDICINE, GENERAL & INTERNAL | END-POINT | AUTOIMMUNE-DISEASES | DOSE IMMUNOSUPPRESSIVE THERAPY | CLINICAL-TRIALS | HEART-FAILURE | DOUBLE-BLIND | LUNG-DISEASE | MARROW-TRANSPLANTATION | PULSE CYCLOPHOSPHAMIDE | SEVERE SYSTEMIC-SCLEROSIS | Follow-Up Studies | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Kaplan-Meier Estimate | Male | Transplantation, Autologous | Hematopoietic Stem Cell Transplantation - mortality | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Infection - etiology | Young Adult | Disease-Free Survival | Scleroderma, Systemic - therapy | Scleroderma, Systemic - mortality | Adolescent | Hematopoietic Stem Cell Transplantation - adverse effects | Intention to Treat Analysis | Adult | Female | Immunosuppressive Agents - adverse effects | Aged | Transplantation Conditioning | Scleroderma, Systemic - drug therapy | Treatment outcome | Care and treatment | Systemic scleroderma | Analysis | Patient outcomes | Scleroderma (Disease) | Stem cells | Transplantation | CD34 antigen | Medical research | Autografts | Kidneys | Transplants & implants | Toxicity | Hypersensitivity | Stem cell transplantation | Sclerosis | Immunosuppressive agents | Hemopoiesis | Cyclophosphamide | Immunosuppression | Infectious diseases | Systemic sclerosis | Renal failure | Skin | Scleroderma | Heart diseases | Kidney transplantation | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Journal Article
Journal Article
Arthritis & Rheumatology, ISSN 2326-5191, 09/2018, Volume 70, Issue 9, pp. 1470 - 1480
ObjectiveTo evaluate the clinical efficacy and safety of baminercept, a lymphotoxin β receptor IgG fusion protein (LTβR‐Ig), for the treatment of primary... 
Lymphotoxin | Sjogren's syndrome | Enumeration | Cytokines | Toxicity | Liver | Immunoglobulin G | CXCL13 protein | Medical services | Lymphocytes T | Patients | Incidence | Proteins | Signaling | Lymphocytes B | Lymphocytes | Peripheral blood | Plasma levels | Fusion protein | Chemokines
Journal Article
Journal Article
Diabetes Care, ISSN 0149-5992, 06/2016, Volume 39, Issue 6, pp. e76 - e78
Mixed-meal tolerance tests (MMTTs) are used in clinical trials to evaluate β-cell function in patients with new-onset type 1 diabetes (1,2). In the T1DAL... 
ENDOCRINOLOGY & METABOLISM | PHASE-2 TRIAL | Clinical trials | Medical tests | Immunology | Diabetes | Index Medicus | Observations | e-Letters
Journal Article